Novosanis receives European funding for its Colli-Pee™ device

Novosanis has received a grant from the European Commission to provide the Colli-PeeTM device, as a non-invasive, user-friendly self-sampling device suited for home-based collection to non-attendees in cervical screening programmes. In particular, the Colli-Pee™ device allows for standardized collection of first void urine (first 20ml of the urine stream) in which human papilloma virus (a virus able to cause cervical cancer) can be detected. Additionally, the grant will also allow Novosanis preparing a pan-European clinical trial to assess the use of first void urine collected using Colli-Pee™ in clinical practice.

Vanessa Vankerckhoven, CEO Novosanis, says: “We are extremely proud to be considered by the European Commission as one of the companies with the most innovative ideas in the world. This exceptional grant in the framework of the European Commission’s Horizon 2020 program is specifically aimed at supporting SMEs. After a successful feasibility study, Novosanis aims at applying for additional subsidies that will not only allow conducting clinical trials in the EU28, but also boost the use of the Colli-Pee™ device as part of the cervical screening programs at European level and beyond.”

VALPAS or in full: ‘VALidation of human PApilloma virus assays on Self-collected first void urine samples’ is a feasibility study. Interestingly, at the second cut-off date of 2015, only three Belgian SMEs obtained Phase 1 funding including Novosanis. Last year a total of 13 Belgian SMEs received Phase 1 funding. Novosanis strives to submit a succeeding phase 2 proposal spring 2016. (http://ec.europa.eu/easme/en/news/142-highly-innovative-smes-funded-hori...)From September 17 to September 21, 2015 the 30th International Papillomavirus Conference will take place in Lisbon, Portugal. Novosanis will have a booth at the conference and will be presenting their latest results on detection of HPV in urine samples and use of the Colli-Pee™ device to reach non-attendees in the screening programs during the scientific poster sessions.

About Novosanis

Novosanis aims to improve quality of life and healthcare by making health and care accessible, acceptable and affordable for everyone. Novosanis strives to enable detection, treatment and prevention of infectious diseases, including sexually transmitted infections, and early stage cancer by developing innovative, safe, and user-friendly medical devices.

Novosanis is a medical device company active in the field of infectious diseases and oncology. We currently have two device (platforms) in portfolio: VAX-ID™, suited for accurate intradermal injections and Colli-Pee™, suited for standardized collection of first void urine.

About H2020 SME Instrument

Small and Medium-sized Enterprises (SME) that are EU-based or established in a country associated to Horizon 2020 can receive EU funding and support for innovation projects that will help them grow and expand their activities into other countries – in Europe and beyond. The funding opportunities for SMEs consist of an optional phase 1 project and a phase 2 project. The optional Phase 1 contains a feasibility assessment lasting around 6 months, to explore and assess the technical feasibility and commercial potential of a breakthrough innovation that a company wants to exploit and commercialize. Phase 2 proposals should address an innovation project lasting around 1 or 2 years, underpinned by a sound and strategic business plan derived from the optional phase 1 project.

Novosanis submitted its phase 1 proposal in June 2015, specifically in response to the call for clinical research for the validation of biomarkers and/or diagnostic medical devices. In addition, Novosanis strives to submit a succeeding phase 2 proposal spring 2016.

Want to know more?

Vanessa Vankerckhoven, CEO Novosanis, vanessa.vankerckhoven@novosanis.com, +32486761885

Koen Beyers, CTO Novosanis, koen.beyers@novosanis.com, +32477933070